Mefloquine one. Plasma concentrations of the (–)-enantiomer are significantly higher than those for the (+)-enantiomer, and the pharmacokinetics between the two enantiomers are significantly different. The (+)-enantiomer has a shorter half-life than the (–)-enantiomer. According to some research, the (+)-enantiomer is more effective in treating malaria, and the (–)-enantiomer specifically binds to adenosine receptors in the central nervous system, which may explain some of its psychotropic effects. Mefloquine was formulated at Walter Reed Army Institute of Research (WRAIR) in the 1970s shortly after the end of the Vietnam war. Mefloquine was number 142,490 of a total of 250,000 antimalarial compounds screened
Treatment of equine lameness cells may be harvested from other horses ahead of time to have banked for immediate treatment of an injury, but there is some concerns of graft-vs-host disease. Stem cells have been used to treat a variety of injuries in horses. The most research has been performed on stem cells used for treatment of tendon and meniscal injuries. Horses with tendonitis treated with bone marrow derived stem cells had a significantly lower re-injury rate compared to those without treatment. Stem cell treatment in damaged tendons is thought to improve the collagen make-up of the tendon while healing. It has been shown